Comparative Pharmacology
Head-to-head clinical analysis: CLONAZEPAM versus NIRAVAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLONAZEPAM versus NIRAVAM.
CLONAZEPAM vs NIRAVAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhances GABA-A receptor inhibitory neurotransmission by binding to benzodiazepine binding site, increasing frequency of chloride channel opening, leading to neuronal hyperpolarization.
NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.
0.5 mg orally three times daily; maximum 20 mg/day
0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.
None Documented
None Documented
Terminal elimination half-life: 19-60 hours (mean 30-40 hours); clinical context: long-acting benzodiazepine, allows once or twice daily dosing; accumulation occurs with repeated use.
Clinical Note
moderateClonazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Fluconazole
Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Renal: 50-70% as metabolites (mostly glucuronide conjugates), <2% unchanged; fecal: 10-20%; biliary: minor.
Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Fluconazole can be decreased when combined with Clonazepam."